Addressing the challenges to immunization practice with an economic algorithm for vaccine selection

Vaccine

Volumn 16, Issue 19, 1998, Pages 1885-1897

  Weniger, Bruce G ^a   Chen, Robert T ^a   Jacobson, Sheldon H ^b   Sewell, Edward C ^c   Deuson, Robert ^a   Livengood, John R ^a   Orenstein, Walter A ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

Author keywords

Biotechnology; Cost control; Decision support techniques; Economics; Formularies; Group purchasing; Immunization; Linear; Operations research; Program; Programming; Vaccines

Indexed keywords

DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; PERTUSSIS VACCINE; TETANUS TOXOID;

ALGORITHM; BIOTECHNOLOGY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG INDUSTRY; IMMUNIZATION; MEDICAL PRACTICE; PRIORITY JOURNAL;

ADOLESCENT; ALGORITHMS; BIOTECHNOLOGY; CHILD; CHILD, PRESCHOOL; COST CONTROL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; POLYSACCHARIDES, BACTERIAL; PROGRAMMING, LINEAR; VACCINATION; VACCINES, CONJUGATE;

EID: 0032210852     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00170-4     Document Type: Conference Paper

References (85)

1. 1 Rennels, M.B., Glass, R.I. and Dennehy, P.H. et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial, United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996, 97(1), 7-13.
2. 2 Perez-Schael, I., Guntinas, M.J. and Perez, M. et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. New England Journal of Medicine 1997, 337(17), 1181-1187.
3. 3 Meurice, F., Parenti, D., Fu, D. and Krause, D.S. Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine. Clinical Infectious Diseases 1997, 25 (Suppl 1), S71-S75.
4. 4 Paradiso, P.R., Hildreth, S.W. and Hogerman, D.A. et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatric Infectious Diseases Journal 1994, 13(9), 792-798.
5. 5 Murphy, B.R., Hall, S.L. and Kulkarni, A.B. et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Research 1994, 32(1), 13-36.
6. 6 Crowe, J.E. Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine 1995, 13(4), 415-421.
7. 7 Falsey, A.R. and Walsh, E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15(10), 1130-1132.
8. 8 McClements, W.L., Armstrong, M.E., Keys, R.D. and Liu, M.A. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine 1997, 15(8), 857-860.
9. 9 Manning, W.C., Paliard, X. and Zhou, S. et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. Journal of Virology 1997, 71(10), 7960-7962.
10. 10 Steller, M.A. and Schiller, J.T. Human papilloma virus immunology and vaccine prospects. Journal National Cancer Institute Monographs 1996, 21, 145-148.
11. 11 CDC. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine - supplementary statement. Morbidity Mortality Weekly Report, 1987, 36(48), 795-798.
12. 12 Ward, J., Lieberman, J.M. and Cochi, S.L., Haemophilus influenzae vaccines. In Vaccines, 2nd edn, eds S.A. Plotkin and E.A. Mortimer Jr. WB Saunders Co., Philadelphia, 1994, pp. 337-386.
13. 13 CDC. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity Mortality Weekly Report, 1997, 46(RR-7), 1-26.
14. 14 Paradiso, P.R. and Lindberg, A.A. Glycoconjugate vaccines: future combinations. Developments in Biology Standards 1996, 87, 269-275.
15. 15 Russo, S., Turin, L., Zanella, A., Ponti, W. and Poli, G. What's going on in vaccine technology? Medicinal Research Reviews 1997, 17, 277-301.
16. 16 Moxon, E.R. Applications of molecular microbiology to vaccinology. Lancet 1997, 350, 1240-1244.
17. 17 Liu, M.A., Overview of DNA vaccines. In DNA vaccines: a new era in vaccinology, eds M.A. Liu, M.R. Hilleman and R. Kurth. Annals of the New York Academy of Sciences, 1995, 772, 15-20.
18. 18 Arntzen, C.I. Pharmaceutical foodstuffs - oral immunization with transgenic plants. Nature Medicine Vaccine Supplement 1998, 4(5), 502-503.
19. 19 Yusibov, V., Modelska, A. and Steplewski, K. et al. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proceedings of the National Academy of Sciences U.S.A. 1997, 94(11), 5784-5788.
20. 20 Dalsgaard, K., Uttenthal, A. and Jones, T.D. et al. Plant-derived vaccine protects target animals against a viral disease. Nature Biotechnology 1997, 15(3), 248-252.
21. 21 Featherstone, C. A green revolution for the clinic? Lancet 1997, 349, 1526.
22. 22 O'Hagan, D.T., Prospects for the development of new and improved vaccines through the use of microencapsulation technology. In New Generation Vaccines, 2nd edn, eds M.M. Levine, G.G. Woodrow, J.B. Kaper and G.S. Cobon. Marcel Dekker Inc, New York, 1997, pp. 215-228.
23. 23 Mannino, R.J. and Gould-Fogerite, S., Antigen cochleate preparations for oral and systemic vaccination. In New Generation Vaccines, 2nd edn, eds M.M. Levine, G.G. Woodrow, J.B. Kaper and G.S. Cobon. Marcel Dekker Inc, New York, 1997, pp. 229-237.
24. 24 Kofler, N., Ruedl, C., Rieser, C., Wick, G. and Wolf, H. Oral immunization with poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres containing pneumotropic bacterial antigens. International Archives of Allergy and Immunology 1997, 113(4), 424-431.
25. 25 Singh, M., Li, X.M. and Wang, H. et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infection and Immunity 1997, 65(5), 1716-1721.
26. 26 CDC. Recommendations of the Immunization Practices Advisory Committee (ACIP): general recommendations on immunization. Morbidity and Mortality Weekly Report, 1989, 38, 205-227.
27. 27 CDC. Recommended childhood immunization schedule - United States, 1998. Morbidity and Mortality Weekly Report, 1998, 47(1), 8-12.
28. 28 Melman, S.T., Chawla, T., Kaplan, J.M. and Anbar, R.D. Multiple immunizations. Archives of Family Medicine 1994, 3, 615-618.
29. 29 Madlon-Kay, D. and Harper, P. Too many shots? Parent, nurse, and physician attitudes toward multiple simultaneous childhood vaccinations. Archives of Family Medicine 1994, 3, 610-613.
30. 30 Askew, G.L., Finelli, L. and Lutz, J. et al. Beliefs and practices regarding childhood vaccination among urban pediatric providers in New Jersey. Pediatrics 1995, 96, 889-892.
31. 31 Woodin, K.A., Rodewald, L.E., Humiston, S.G., Carges, M.S., Schaffer, S.J. and Szilagyi, P.G. Physician and parent opinions: Are children becoming pincushions from immunizations? Archives of Pediatric and Adolescent Medicine 1995, 149, 845-849.
32. 32 Zimmerman, R.K., Bradford, B.J., Janosky, J.E., Mieczkowski, T.A., DeSensi, E. and Grufferman, S. Barriers to measles and pertussis immunization: the knowledge and attitudes of Pennsylvania primary care physicians. American Journal of Preventive Medicine 1997, 13, 89-97.
33. 33 Dietz, V.J., Stevenson, J., Zell, E.R., Cochi, S., Hadler, S. and Eddins, D. Potential impact on vaccination coverage levels by administering vaccines simultaneously and reducing dropout rates. Archives of Pediatric and Adolescent Medicine 1994, 148, 943-949.
34. 34 Lieu, T.A., Shinefield, H.R., Ray, P., Sorel, M.E. and Black, S.B. Would better adherence to guidelines improve childhood immunization rates? Pediatrics 1996, 98, 1062-1068.
35. 35 Wood, D., Pereyra, M., Halfon, N., Hamlin J. and Grabowski, M. Vaccination levels in Los Angeles public health centers: the contribution of missed opportunities to vaccinate and other factors. American Journal of Public Health 1995, 85, 850-853.
36. 36 Holt, E., Guyer, B. and Hughart, N. et al. The contribution of missed opportunities to childhood underimmunization in Baltimore. Pediatrics 1996, 97, 474-480.
37. 37 Hutchins, S.S., Escolan, J. and Markowitz, L.E. et al. Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. Pediatrics 1989, 83, 369-374.
38. 38 Aylward, B., Lloyd, J., Zaffran, M., McNair-Scott, R. and Evans, P. Reducing the risk of unsafe injections in immunization programmes: financial and operational implications of various injection technologies. Bulletin of the World Health Organization 1995, 73(4), 531-540.
39. 39 Aylward, B., Kane, M., McNair-Scott, R. and Hu, D.J. Model-based estimates of the risk of human immunodeficiency virus and hepatitis B virus transmission through unsafe injections. International Journal of Epidemiology 1995, 24, 446-452.
40. 40 Institute of Medicine, The Children's Vaccine Initiative: Achieving the Vision. eds Mitchel, V.S., Philipose, N.M., Sanford, J.P. National Academy Press, Washington, D.C., 1993.
41. 41 Walker, R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12, 387-400.
42. 42 Curtiss 3rd, R., Kelly, S.M. and Tinge, S.A. et al. Recombinant Salmonella vectors in vaccine development. Developments in Biological Standardization 1994, 82, 23-33.
43. 43 Noriega, F.R., Wang, J.Y., Losonsky, G., Maneval, D.R., Hone, D.M. and Levine, M.M. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infection and Immunity 1994, 62(11), 5168-5172.
44. 44 Kendal, A.P. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? European Journal of Epidemiology 1997, 13(5), 591-609.
45. 45 Belshe, R.B., Mendelman, P.M. and Treanor, I. et al. The efficacy of live attenuated, cold adapted, trivalent intranasal influenza virus vaccine in children. New Engl J Med 1998, 338, 1405-1412.
46. 46 Reis, E.C., Jacobson, R.M., Tarbell, S. and Weniger, B.G. Taking the sting out of shots-control of vaccine-associated pain and adverse reactions. Pediatr Annals 1998, 27, 375-385.
47. 47 CDC. Hepatitis B associated with jet gun injection -California. Morbidity and Mortality Weekly Report, 1986, 35(23), 373-376.
48. 48 Canter, J., Mackey, K. and Good, L.S. et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Archives of Internal Medicine 1990, 150(9), 1923-1927.
49. 49 Global Programme on Vaccines and Immunization. Report of the steering group on the development of jet injection for immunization, 18-19 March 1997. World Health Organization, Geneva, pp. 1-37.
50. 50 Williams, R.S., Johnston, S.A., Riedy, M., DeVit, M.J., McElligott, S.G. and Sanford, J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proceedings of the National Academy of Sciences U.S.A. 1991, 88(7), 2726-2730.
51. 51 Raz, E., Carson, D.A. and Parker, S.E. et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proceedings of the National Academy of Sciences U.S.A. 1994, 91(20), 9519-9523.
52. 52 Bellhouse, B.J., Sarphie, D.F. and Greenford, J.C., Method of delivering powder transdermally with needleless injector. US Patent 5,630,796 issued 20 May 1997.
53. 53 Tang, D.-C., Shi, Z. and Curiel, D.T. Vaccination onto bare skin. Nature 1997, 388, 729.
54. 54 Glenn, G.M., Rao, M., Matyas, G.R. and Alving, C.R. Vaccination onto bare skin. Nature 1998, 388, 729.
55. 55 Abbott, K. and Fowler-Kerry, S. The use of a topical refrigerant anesthetic to reduce injection pain in children. Journal of Pain and Symptom Management 1995, 10, 584-590.
56. 56 Parkman, P.D. Combined and simultaneously administered vaccines: a brief history. In Combined vaccines and simultaneous administration: current issues and perspectives, eds J.C. Williams, K.L. Goldenthal, D.L. Burns B.P. Lewis Jr., Annals of the New York Academy of Sciences, 1995, 754, 1-9.
57. 57 Anthony, B.F. FDA perspective on regulatory issues in vaccine development. In Combined vaccines and simultaneous administration: current issues and perspectives, eds J.C. Williams, K.L. Goldenthal, D.L Burns B.P. Lewis Jr., Annals of the New York Academy of Sciences, 1995, 754, 10-16.
58. 58 Corbel, M.J., Control testing of combined vaccines: a consideration of potential problems and approaches. In Proceedings of the 2nd European Conference on Vaccinology: Combined Vaccines for Europe - Pharmaceutical, Regulatory and Policy-making Aspects, eds F. André, J. Cholat and I. Furminger. Biologicals, 1994, 22, 353-360.
59. 59 Insel, R.A., Potential alterations in immunogenicity by combining or simultaneously administering vaccince components. In Combined vaccines and simultaneous administration: current issues and perspectives, eds J.C. Williams, K.L. Goldenthal, D.L. Burns B.P. Lewis Jr., Annals of the New York Academy of Sciences, 1995, 754, 35-47.
60. 60 White, C.J., Stinson, D. and Staehle, B. et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clinical Infectious Diseases 1997, 24, 925-931.
61. 61 Granoff, D.M. Challenges for licensure of new diphtheria, tetanus, acellular pertussis (DTaP) combination vaccines: point. Pediatric Infectious Diseases Journal 1996, 15(12), 1069-1070.
62. 62 Granoff, D.M. and Rappuoli, R. Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Developments in Biological Standardization 1997, 89, 379-389.
63. 63 Pauly, M.V., Robinson, C.A., Sepe, S.J., Sing, M. and Willian, M.K., (eds) Supplying Vaccines: An Economic Analysis of Critical Issues. IOS Press, Washington, D.C., 1996, pp. 1-225.
64. 64 CDC. FDA approval of a Haemophilus b conjugate vaccine combined by reconstitution with an acellular pertussis vaccine. Morbidity and Mortality Weekly Report, 1996, 45, 993-995.
65. 65 CDC. FDA approval of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine. Morbidity and Mortality Weekly Report, 1997, 46, 107-109.
66. 66 General Services Administration. Federal Acquisition Regulations: Statement of guiding principles for the federal acquisition system (§1.102); Definitions ['best value'] (§2.101); Best value continuum (§15.101); Tradeoff process (§15.101-1). Superintendent of Documents, US Government Printing Office, Washington, D.C., 1990 (as revised by Federal Acquisition Circular-FAC 97-02, Federal Register: September 30, 1997;62(189):51230-51231).
67. 67 Woodruff, B.A., Stevenson, J. and Yusuf, H. et al. Progress toward integrating hepatitis B vaccine into routine infant immunization schedules in the United States, 1991 through 1994 - Connecticut Hepatitis B Project Group. Pediatrics 1996, 97(6), 798-803.
68. 68 Gafni, A. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs. Medical Care 1991, 29(12), 1246-1252.
69. 69 Robinson, R. Cost-benefit analysis. British Medical Journal 1993, 307, 924-926.
70. 70 Chestnut, L.G., Keller, L.R., Lambert, W.E. and Rowe, R.D. Measuring heart patients' willingness to pay for changes in angina symptoms. Medical Decision Making 1996, 16, 65-77.
71. 71 Lawrence, K. and Zanakis, S., Production Planning and Scheduling: Mathematical Programming Applications. Industrial Engineering and Management Press, Atlanta, GA, 1984.
72. 72 Shapiro, J., Optimization Models for Planning and Allocation: Text and Cases in Mathematical Programming. John Wiley and Sons, New York, 1984.
73. 73 Lilien, G. and Kotler, P., Marketing Decision Models. Harper and Row, New York, 1983.
74. 74 Weingartner, H., Mathematical Programming and the Analysis of Capital Budgeting. Prentice Hall, Englewood Cliffs, NJ, 1963.
75. 75 Rothstein, M. Hospital manpower shift scheduling by mathematical programming. Health Services Research 1973, 8, 60-66.
76. 76 Rohn, E. A new LP approach to bond portfolio management. Journal of Financial and Quantitative Analysis 1987, 22, 439-467.
77. 77 Hilal, S. and Erikson, W. Matching supplies to save lives: linear programming the production of heart valves. Interfaces 1981, 11, 48-56.
78. 78 Jacobson, S.H., Sewell, E.C., Deuson, R. and Weniger, B.G. An integer programming model for vaccine procurement and delivery for childhood immunization: a pilot study. Health Care Management Science 1998, 1, (in press).
79. 79 CDC, Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and Mortality Weekly Report, 1991,40(RR-10), 1-28.
80. 80 Halsey, N.A., Practical considerations regarding the impact on immunization schedules of the introduction of new combined vaccines. In Combined vaccines and simultaneous administration: current issues and perspectives, eds J.C. Williams, K.L. Goldenthal, D.L. Burns B.P. Lewis Jr., Annals of the New York Academy of Sciences, 1995, 754, 250-254.
81. 81 National Center for Health Statistics, Health, United States, 1996-97 and Injury Chartbook. Hyattsville, Maryland, 1997.
82. 82 Hackett, L.B. and Totten, J.T., Report on the United States vaccine industry; commissioned by the Department of Health and Human Services. Mercer Management Consulting Inc. Washington, D.C., 14 June 1995.
83. 83 CDC. Biologics Surveillance, Report no. 94, 1991-1995. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA, 1997.
84. 84 CDC. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 1997. Morbidity and Mortality Weekly Report, 1998, 47, 547-554.
85. 85 de Quadras, C.A., Carrasco, P. and Olive, J.M. The desired field-performance characteristics of new improved vaccines for the developing world. International Journal of Technology Assessment in Health Care 1994, 10, 65-70.